## Food and Drug Administration, HHS

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

 $[40~{\rm FR}~13873,~{\rm Mar.}~27,~1975,~{\rm as~amended~at}~43~{\rm FR}~18172,~{\rm Apr.}~28,~1978]$ 

## § 524.1484d Neomycin sulfate, hydrocortisone acetate, tetracaine hydrochloride ear ointment.

- (a) Specifications. The product contains 5 milligrams of neomycin sulfate, equivalent to 3.5 milligrams of neomycin base, 5 milligrams of hydrocortisone acetate, and 5 milligrams of tetracaine hydrochloride in each gram of ointment.
- (b) *Sponsor*. See No. 000009 in §510.600(c) of this chapter.
- (c) Conditions of use. (1) It is indicated for treating acute otitis externa and, to a lesser degree, chronic otitis externa in dogs and cats. In treatment of ear canker and other inflammatory conditions of the external ear canal, a quantity of ointment sufficient to fill the external ear canal may be applied one to three times daily.<sup>1</sup>
- (2) Tetracaine and neomycin have the potential to sensitize. Care should be taken to observe animals being treated for evidence of hypersensitivity or allergy to the product. If such signs are noted, therapy with the product should be stopped. Incomplete response or exacerbation of corticosteroid responsive lesions may be due to the presence of nonsusceptible organisms or to prolonged use of antibiotic-containing preparations resulting in overgrowth of nonsusceptible organisms, particularly Monilia.<sup>1</sup>
- (3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.<sup>1</sup>
- [40 FR 13873, Mar. 27, 1975, as amended at 49 FR 21922, May 24, 1984]

## § 524.1484e Neomycin sulfate and polymyxin B sulfate ophthalmic solution.

(a) Specifications. Each milliliter of the ophthalmic preparation contains

- 5.0 milligrams neomycin sulfate (3.5 milligrams neomycin base), and 10,000 Units of polymyxin B sulfate.
- (b) Sponsor. See No. 000856 in \$510.600(c) of this chapter.
- (c) Conditions of use. (1) The drug is recommended for the treatment of bacterial infections associated with topical ophthalmological conditions such as corneal injuries, superficial keratitis, conjunctivitis, keratoconjunctivities, and blepharitis in the dog.
- (2) The recommended dosage is 1 to 2 drops per eye every 6 hours.
- (3) In treating ophthalmological conditions associated with bacterial infections the drug is contraindicated in those cases in which microorganisms are nonsusceptible to the antibiotics incorporated in the drug.
- (4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 61 FR 5507, Feb. 13, 1996]

## § 524.1484f Neomycin sulfate, prednisolone acetate, tetracaine hydrochloride eardrops.

- (a) Specifications. The product contains 5 milligrams of neomycin sulfate equivalent to 3.5 milligrams of neomycin base, 2.5 milligrams of prednisolone acetate, and 5 milligrams of tetracaine hydrochloride in each milliliter of sterile suspension.
- (b) *Sponsor*. See No. 000009 in §510.600(c) of this chapter.
- (c) Conditions of use. (1) It is useful in treating such conditions as acute otitis externa and, to a lesser degree, chronic otitis externa in dogs and cats. It is indicated as treatment or adjunctive therapy of certain ear conditions in dogs and cats caused by or associated with neomycin-susceptible organisms and/or allergy. In otitis externa, 2 to 6 drops may be placed in the external ear canal two or three times daily.<sup>1</sup>
- (2) Incomplete response or exacerbation of corticosteroid responsive lesions may be due to the presence of nonsusceptible organisms or to prolonged use of antibiotic-containing preparations resulting in overgrowth of nonsusceptible organisms, particularly Monilia. Thus, if improvement is not noted within 2 or 3 days, or if redness,

<sup>&</sup>lt;sup>1</sup>These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information